Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

NCT03270007 is registered in ClinicalTrials.gov with Tao OUYANG as lead sponsor.

NCT NCT03270007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03270007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy
Lead sponsor
Tao OUYANG
Phase
Phase 4
Overall status
Unknown status
Start date
November 10, 2017
Completion date
December 31, 2024
Enrollment
304 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary breast cancer